{"doi":"10.1507/endocrine.98.1_123","title":"抄録，抄録（一般演題口演），抄録（一般演題ポスター），人名索引，キーワード索引，定款，定款施行細則，賛助会員","abstract":"Pheochromocy toma is a catecholamine-secreting tumor is usually localized to the adrenal gland.It is frequently sought and rarely found.When correctly diagnosed and properly treated, it is curable; when undiagnosed or improperly treated, it can be fatal.The prevalence is 0.01% to 0.1% of the hypertensive population.It occurs equally in men and women, primarily in the 3rd through 5th decades.Catecholamine hypersecretion symptoms are present <50% of patients.The mode of diagnosis has changed dramatically o ve r t h e pa s t 100 y r s -i n 2022, 60% a r e d i sc o ve r ed a s a d r e n a l i n c i d e n t a l om a s.When small (eg, <1.5 cm), pheochromocytomas are not large enough to make enough catechols to be biochemically detectable and some are nonfunctional.So, it is key for endocrinologists to know what pheochromocytomas \"look like\" on cross sectional imaging.Pheochromocytomas are lipid poor on CT scan.If the unenhanced CT attenuation of an adrenal mass is <10 HU, it cannot be a pheochromocytoma.In a patient with spells, the degree of elevation in fractionated metanephrines and catecholamines should be markedly abnormal-if a pheochromocytoma is responsible for \"classic spells\", then the biochemical tests are always unequivocally abnormal (eg, >5-fold above the ULN).The tumor can always be found in the symptomatic patient-the average diameter in symptomatic patients is 4.5 cm.Forty percent of patients have a disease-causing germline mutation; genetic testing should be considered in and discussed with all patients.Ga-68 DOTATATE PET CT or FDG-PET CT or 123-I-metaiodobenzylguanidine scintigraphy are indicated if abdominal imaging is negative or if looking for additional paragangliomas or metastatic disease.Patients should be prepared for surgery with alpha-and beta-adrenergic blockade.All pheochromocytomas and paragangliomas have malignant potential-ignore the pathology report that uses the word \"benign.\"All patients should have life-long annual biochemical follow-up to detect either metachronous tumors or metastatic disease.","journal":"Folia Endocrinologica Japonica","year":2022,"id":307012,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8869,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":1,"raw_metadata":null,"created_at":"2026-07-19T00:32:52.703737Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}